Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Dupont, C. Glynos, T. Vassilakopoulos, A. Papapetropoulos, P. Brouckaert, A. Giannis, G. Joos, K. Bracke, G. Brusselle (Ghent, Belgium; Athens, Patras, Greece; Leipzig, Germany). The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease. Eur Respir J 2013; 42: Suppl. 57, 4860

Member's Comments

No comment yet.

Related content which might interest you: The role of guanylyl cyclase in resistive breathing Source: Annual Congress 2013 –Experimental models in critical care Year: 2013 Fractional exhaled nitric oxide in chronic obstructive pulmonary disease Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 The cycle of the nitric oxide metabolism in patients with COPD and chronic cerebrovascular diseases (CCVD) Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013 The role of inducible NO synthase (iNOS) in a cell model of steroid resistance in chronic obstructive pulmonary disease Source: Annual Congress 2008 - Basic science in asthma and COPD Year: 2008 Use of different exhaled nitric oxide multiple flow rate models in COPD Source: Eur Respir J 2007; 29: 651-659 Year: 2007 Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008 Exhaled nitric oxide in respiratory diseases other than asthma Source: Eur Respir Monogr 2010; 49: 45-55 Year: 2010 Nitric oxide in the COPD pathogenesis in patients with pulmonary tuberculosis Source: International Congress 2019 – Oxidative stress, hypoxia and microbial exposure in the pathogenesis of pulmonary disease Year: 2019 Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function Source: Eur Respir J 2001; 17: 934-938 Year: 2001 Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction? Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019 Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral vs. central airways Source: Eur Respir J 2003; 22: Suppl. 45, 279s Year: 2003 Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways Source: Eur Respir J 2003; 22: 457-461 Year: 2003 Nitric oxide modulates vascular remodelling in a model of chronic allergic lung inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 432s Year: 2006 Role of nitric oxide pathway in pathogenesis of high altitude pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 551s Year: 2007 Gene polymorphisms of endothelial nitric oxide synthase in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Source: Eur Respir J 2007; 30: 26-30 Year: 2007 Role of fractional exhaled nitric oxide(FeNO) in obstructive airway diseases in Indian population Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015